Nasdaq GlobeNewswire

Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts

PHILADELPHIA and OXFORD, United Kingdom, July 18, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of safety data from the second dose cohort of patients who received one billion transduced SPEAR T‑cells targeting MAGE-A10 in the non-small cell lung cancer (NSCLC) study. Based on these data, the Safety Review Committee (SRC) has endorsed dose escalation to the third dose cohorts in both MAGE-A10 pilot studies (i.e., the NSCLC and the triple tumor studies).

Myriad Announces Coverage Decision by Kroger® Prescription Plans for Vectra DA®

SALT LAKE CITY, July 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide  Vectra® DA as a benefit option for Kroger Prescription Plan employer group clients.   

Magnesium Phosphate Market to hit $1.5bn by 2024: Global Market Insights, Inc.

Magnesium Phosphate Market Regional Analysis covering 20+ Countries and 18 Company Profiles (Jost Chemical, American Elements, Anmol Chemicals Group, Celtic Chemicals, Hap Seng, Hindustan Phosphate, Innophos Holdings, Manus Aktteva Biopharma, The Mosaic Company, Nikunj Chemicals, Nithyasri Chemicals, Nexgen Chemicals, Powder Pack Chem, Pacific Chemicals Company, Refractory Minerals Company, Redox, Shanpar, Triveni Chemicals) & Forecasts to 2024

SOHM, Inc. Reports $180,000 of Total Revenue and a Gross Profit of $95,292 for the First Qtr of 2018

Chino Hills, CA, July 17, 2018 (GLOBE NEWSWIRE) -- SOHM, Inc. (PINKSHEETS: SHMN) a globally-known generic pharmaceutical manufacturer, release its first Qtr of 2018. 

Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops

Research to Explore Potential for CAP-2003 to Address Trauma-related Injuries

CytoDyn to Present at Singular Summer Solstice 2018 Conference on July 19

VANCOUVER, Washington, July 16, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody, announces that Nader Pourhassan, Ph.D., President and CEO, will present at the Singular Research Summer Solstice 2018 Conference on Thursday, July 19, at 2:50 p.m. Eastern time (11:50 a.m. Pacific time).  The conference is being held at the Convene Conference Center in New York City.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2018 Financial Results

OLDSMAR, Fla., July 16, 2018 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTCQB:CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2018. 

Nohla Therapeutics Receives FDA Orphan Drug Designation for Dilanubicel for Hematopoietic Stem Cell Transplant Patients

SEATTLE, July 16, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nohla’s lead product candidate, dilanubicel (NLA101), Orphan Drug Designation for reduction of morbidity and mortality associated with hematopoietic stem cell transplant (HSCT). Dilanubicel received Orphan Drug Designation from the European Commission in January 2018.

Diamond Equity Research Initiates Coverage on AquaBounty Technologies Inc. (NASDAQ: AQB) with a Valuation of $4.25 Per Share

NEW YORK, July 16, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of AquaBounty Technologies Inc. (NASDAQ:AQB). The in-depth 25-page initiation report includes detailed information on the AquaBounty business model, services, industry, valuation, management and risks.

CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial

Approximately 81% of patients completing PRO 140 trial demonstrated suppressed viral load with plasma HIV-1 RNA viral load of less than 50 copies/mL and 92% had viral load of less than 400 cp/mL

Arrayit Corporation Reports Clinical Instrumentation Sale to the United States Food and Drug Administration


Sunnyvale, July 16, 2018 (GLOBE NEWSWIRE) -- July 16, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, announces the sale of clinical instrumentation to the United States Food and Drug Administration (FDA). Arrayit uses the same clinical instrumentation in its Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the Centers for Medicare and Medicaid Services (CMS) and the State of California Department of Public Health (CDPH).  The instrumentation reads and reports test results for the company’s allergy and dietary wellness tests and pipeline tests for ovarian cancer and Parkinson’s Disease (PD).

Veloxis Pharmaceuticals A/S Grants Warrants Under Existing Warrant Program

Company Release no. 13/2018

CytoDyn to Hold Investment Community Conference Call on July 17, 2018

VANCOUVER, Washington, July 13, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announces that management will host an investment community conference call to provide a business update. 

CytoDyn Announces Leadership Changes to Align with Expanded Focus of PRO 140 to Cancer and Immunological Disorders

VANCOUVER, Washington, July 12, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody, announces leadership changes that align with the strategic expansion of its focus with PRO 140 to cancer and immunological disorders, separately announced today.

CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders

  • Announces non-binding Letter of Intent to acquire CCR5-focused cancer company ProstaGene LLC
  • Maintains commitment to advancing PRO 140 clinical programs in HIV and graft-versus-host disease
  • Advancing plans to submit BLA for PRO 140 in combination therapy for HIV

Cytokinetics to Announce Second Quarter Results on July 26, 2018

SOUTH SAN FRANCISCO, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on July 26, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.

ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July


ViaDerma Provides an Update to Shareholders via a Letter from the CEO

The Company is also in early stage discussions to sell its product on TV

Nohla Therapeutics Announces Second Closing of $56 Million Series B Financing

Additional $11 Million Raised from Three New International Investors and One Existing Investor

NewLink Genetics to Host Its Second Quarter 2018 Financial Results Conference Call on July 31, 2018


AMES, Iowa, July 10, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its second quarter 2018 financial results on Tuesday, July 31, 2018. The company has scheduled a conference call for 4:30 PM ET the same day to discuss these results and to give an update on its clinical development, corporate strategy and cash guidance.